Tianeptine

Unlike the steroids and pure research chemicals elsewhere in this collection, it has a real regulatory pedigree and a real clinical evidence base: it is approved and prescribed for major depressive disorder — and for anxious or somatic depression — in parts of Europe, Asia and Latin America, typically at 12.5 mg three times daily (37.5 mg/day).

Multiple randomized, double-blind trials and a meta-analysis support short-term antidepressant efficacy.

A meta-analysis of five RCTs in 1,348 patients found tianeptine at least as effective as SSRIs with a trend toward better acceptability (Kasper & Olié 2002); a 3-month randomized double-blind trial versus paroxetine in 277 outpatients found it as effective and as safe (Waintraub 2002); and a 6-week randomized double-blind trial versus fluoxetine in 178 patients found comparable response rates (Novotny & Faltus 2002).

At the therapeutic dose it is generally well tolerated. So far, this reads like a legitimate antidepressant — and abroad, under prescription and supervision, that is largely what it is. The mechanism is the twist.

Tianeptine was long described as an unusual modulator of glutamatergic signalling and hippocampal/amygdalar plasticity that helps reverse stress-induced remodelling — an account that made it sound benign.

But in 2014 it was definitively shown to be a full agonist at the mu-opioid receptor (MOR), with measurable binding affinity and functional potency, and a lower-potency delta-opioid agonist (Gassaway 2014).

The mu-opioid action is now understood to be the trigger for its antidepressant and anxiolytic effects — and it is also, unavoidably, the source of its abuse potential. That single fact reframes everything that follows.

Because tianeptine is a mu-opioid agonist, it can be misused for opioid-like euphoria, it produces tolerance and physical dependence, and stopping it precipitates an opioid-like withdrawal syndrome.

In the United States, where it has never been FDA-approved, this has played out as a public-health problem rather than a treatment story.

It is sold — illegally and unapproved — as a 'nootropic' or dietary 'supplement' under names like Tianaa, Za Za and Pegasus, and is nicknamed 'gas station heroin' because it is bought over the counter at convenience stores and produces an opioid high.

The FDA has warned consumers about it and acted against products containing it.

The dominant recent US literature is therefore not about depression: it is case reports of abuse and dependence (a review of 18 cases found a clear potential for abuse and addiction, especially in people with substance-use histories — Springer & Cubała 2018), severe opioid-like withdrawal, overdose with CNS and respiratory depression (typically at doses many times the 37.5 mg/day therapeutic dose, sometimes grams per day), and national poison-center surveillance showing exposures rising sharply over 2014-2017 with neurologic, cardiovascular and gastrointestinal effects and documented withdrawal (El Zahran 2018).

The evidence score reflects this duality squarely: there is genuine, replicated short-term antidepressant efficacy at the prescribed dose — better than most compounds in this gated tier — but the mu-opioid agonism, the abuse/dependence/withdrawal liability, the overdose risk at the supratherapeutic doses people actually misuse, and the absence of any US approval keep it modest and firmly in caution territory.

This entry exists to inform honestly, not to recommend: tianeptine is a real antidepressant abroad and a dangerous, unapproved opioid-acting drug of abuse in the US, and nothing here should be read as guidance to obtain or self-administer it.